PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 30, 2026Vaccine X0 citationsOpen Access

Association between village coverage of 13-valent pneumococcal conjugate vaccine and vaccine-type pneumococcal carriage among children aged 0–59 months with pneumonia in Papua New Guinea: an observational study

View Full Paper
RFRebecca L. FordENEleanor FG NealJSJoycelyn Sapura

Key Points

  • This research assesses the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) against pneumococcal carriage in children with pneumonia.
  • Enrolled children aged ≤59 months with pneumonia or suspected meningitis from 2016 to 2019.
  • Collected clinical data, PCV13 vaccination status, and nasopharyngeal swabs.
  • Used lytA real-time PCR for pneumococcal detection and microarray for serotyping.
  • Estimated village-level PCV13 coverage through household surveys and analyzed data using generalized estimating equations.
  • Vaccine-type pneumococcal carriage was significantly lower in vaccinated children (24.8%) compared to those under-vaccinated (41.3%).
  • Adjusted effectiveness of PCV13 against vaccine-type carriage was 46.6%.
  • Village-level PCV13 coverage increased from 12.5% in 2016 to 28.6% in 2019.
  • Each 1% increase in village coverage resulted in a 0.5% decrease in vaccine-type carriage.

Abstract

Pneumococcal conjugate vaccine (PCV) prevents pneumococcal disease and pneumonia, but indirect effects are poorly understood in low-coverage, high-burden settings like Papua New Guinea (PNG). PNG introduced 13-valent PCV (PCV13) in 2014. We aimed to assess direct and indirect effectiveness of PCV13 against vaccine-type pneumococcal carriage among children with pneumonia or suspected meningitis in PNG. Children aged ≤59 months with pneumonia or suspected meningitis (cases) were enrolled at Eastern Highlands Provincial Hospital and nearby clinics (April 2016–December 2019). Clinical data, PCV13 status, and nasopharyngeal swabs were collected. Pneumococci were detected by lytA real-time PCR and serotyped by microarray. PCV13 coverage among village children ≤59 months was estimated via household surveys. Vaccine-type carriage by case-level PCV13 status was estimated. Associations between carriage and case PCV13 status (direct effects), and village-level coverage (indirect effects) were estimated using GEE logistic regression with village clustering. Among 1214 cases, vaccine-type carriage was lower in vaccinated (24.8%) than under-vaccinated (41.3%) cases. Adjusted PCV13 effectiveness against vaccine-type carriage was 46.6% (95% CI 27.0–60.9). Coverage surveys occurred in 148 villages (5978 children). Median village-level coverage increased from 2016 (12.5% IQR 0–37.5) to 2019 (28.6% IQR 0–53.8). Each percent increase in village coverage corresponded to a 0.5% (95% CI 0.0–1.0) decrease in vaccine-type carriage. PCV13 vaccination reduced vaccine-type carriage in PNG. Despite low coverage, indirect effects were evident, consistent with emerging herd protection. These findings highlight the importance of strengthening PCV13 programs to optimise individual and community protection. • PCV13 reduced vaccine-type pneumococcal carriage among children in PNG. • Higher village PCV13 coverage was linked to lower vaccine-type carriage despite low/uneven uptake. • Vaccine-type carriage persisted even as PCV13 coverage increased. • Overall carriage stayed high; non-vaccine-type carriage was higher among vaccinated children.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ford et al. (2026) studied this question.

synapsesocial.com/papers/69ca1280883daed6ee095010https://doi.org/10.1016/j.jvacx.2026.100811
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–20212024 · 5 citations
  2. 2Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia2024 · 5 citations
  3. 3Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction and Before a Schedule Change2024 · 1 citations
  4. 4Sustained impact of 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Kenya, 2011-20222024
  5. 5Natural carriage of <i>Streptococcus pneumoniae</i> is associated with increased experimental pneumococcal carriage but reduced conjugate vaccine efficacy in a human challenge model2024